The global burden of chronic urticaria for the patient and society

M Gonçalo 1, A Gimenéz-Arnau 2, M Al-Ahmad 3, M Ben-Shoshan 4, J A Bernstein 5, L F Ensina 6, D Fomina 7 8, C A Galvàn 9, K Godse 10, C Grattan 11, M Hide 12, C H Katelaris 13, M Khoshkhui 14, E Kocatürk 15, K Kulthanan 16, I Medina 17, I Nasr 18, J Peter 19, P Staubach 20, L Wang 21, K Weller 22, M Maurer 22

Affiliations

01 February 2021

-

doi: 10.1111/bjd.19561

Abstract

Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and middle-aged women. It usually lasts for several years (> 1 year in 25-75% of patients) and often takes > 1 year before effective management is implemented. It presents as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) or both in the same person. More than 25% of cases are resistant to H1 -antihistamines, even at higher doses, and third- and fourth-line therapies (omalizumab and ciclosporin) control the disease only in two-thirds of H1 -antihistamine-resistant patients. Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society. CU may have a strong impact on health-related quality of life (HRQoL), particularly when CSU is associated with angio-oedema and/or CIndU (Dermatology Life Quality Index > 10 in 30% of patients). Comorbidities, such as anxiety and depression, which are present in more than 30% of patients with CSU, compound HRQoL impairment. Severe pruritus and the unpredictable occurrence of weals and angio-oedema are responsible for sleep disorders; sexual dysfunction; limitations on daily life, work and sports activities; interfering with life within the family and in society; and patients' performance at school and work (6% absenteeism and 25% presenteeism). Apart from treatment costs, with annual values between 900 and 2400 purchasing power parity dollars (PPP$) in Europe and the USA, CU is associated with a high consumption of medical resources and other indirect costs, which may reach a total annual cost of PPP$ 15 550.


 

References

 

  1. Zuberbier T, Aberer W, Asero R et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy 2018; 73:1393-414.
  2. Schoepke N, Asero R, Ellrich A et al. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria (aiCSU): results of the PURIST Study. Allergy 2019; 74:2427-36.
  3. Kolkhir P, Church MK, Altrichter S et al. Eosinopenia in chronic spontaneous urticaria is associated with high disease activity, autoimmunity, and poor response to treatment. J Allergy Clin Immunol Pract 2020; 8:318-25.
  4. Fricke J, Lau S, Ávila G et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy 2020; 75:423-32.
  5. Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and. Br J Dermatol 2016; 175:1153-65.
  6. Lewis Y, Finlay A. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9:169-80.
  7. Balp MM, Khalil S, Tian H et al. Burden of chronic urticaria relative to psoriasis in five European countries. J Eur Acad Dermatol Venereol 2018; 32:282-90.
  8. Grob J, Revuz J, Ortonne J et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005; 152:289-95.
  9. Baiardini I, Giardini A, Pasquali M et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58:621-3.
  10. O’Donnell B, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136:197-201.
  11. Itakura A, Tani Y, Kaneko N, Hide M. Impact of chronic urticaria on quality of life and work in Japan: results of a real-world study. J Dermatol 2018; 45:963-70.
  12. Maurer M, Abuzakouk M, Bérard F et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 2017; 72:2005-16.
  13. Thomsen SF, Pritzier EC, Anderson CD et al. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. J Eur Acad Dermatol Venereol 2017; 31:1048-55.
  14. Weller K, Maurer M, Grattan C et al. ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. Clin Transl Allergy 2015; 5:29.
  15. Balp M-M, Lopes da Silva N, Vietri J et al. The burden of chronic urticaria from Brazilian patients’ perspective. Dermatol Ther 2017; 7:535-45.
  16. Lee N, Lee JD, Lee HY et al. Epidemiology of chronic urticaria in Korea using the Korean Health Insurance Database, 2010-2014. Allergy Asthma Immunol Res 2017; 9:438-45.
  17. Lapi F, Cassano N, Pegoraro V et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy. Br J Dermatol 2016; 174:996-1004.
  18. Maurer M, Staubach P, Raap U et al. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. Br J Dermatol 2016; 174:892-4.
  19. Maurer M, Houghton K, Costa C et al. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organ J 2018; 11:23.
  20. Costa C, Rosmaninho I, Guilherme A et al. Chronic urticaria in the real-life clinical practice setting in Portugal: baseline results from the non-interventional multicentre AWARE study. Acta Med Port 2019; 32:133-40.
  21. Guillet G, Bécherel P-A, Pralong P et al. The burden of chronic urticaria: French baseline data from the international real-life AWARE study. Eur J Dermatol 2019; 29:49-54.
  22. Balp M, Weller K, Carboni V et al. Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatr Allergy Immunol 2018; 29:630-6.
  23. Caffarelli C, Paravati F, El Hachem M et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediat 2019; 45:101.
  24. Magen E, Mishal J, Schlesinger M. Clinical and laboratory features of chronic idiopathic urticaria in the elderly. Int J Dermatol 2013; 52:1387-91.
  25. Curto-Barredo L, Pujol RM, Roura-Vives G, Giménez-Arnau A. Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response. Eur J Dermatol 2019; 29:627-35.
  26. Sussman G, Abuzakouk M, Canonica W et al. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. Allergy 2018; 73:1724-34.
  27. Maurer M, Weller K, Bindslev-Jensen C et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011; 66:317-30.
  28. Magerl M, Altrichter S, Borzova E et al. The definition, diagnostic testing and management of chronic inducible urticarias - update and revision of the EAACI/GA2LEN/EDF/UNEV 2009 consensus panel recommendations. Allergy 2016; 71:780-802.
  29. Silpa-archa N, Kulthanan K, Pinkaew S. Physical urticaria: prevalence, type and natural course in a tropical country. J Eur Acad Dermatol Venereol 2011; 25:1194-9.
  30. Humphreys F, Hunter JAA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998; 138:635-8.
  31. Netchiporouk E, Sasseville D, Moreau L et al. Evaluating comorbidities, natural history, and predictors of early resolution in a cohort of children with chronic urticaria. JAMA Dermatol 2017; 153:1236-42.
  32. Davis MDP, Van Der Hilst JCH. Mimickers of urticaria: urticarial vasculitis and autoinflammatory diseases. J Allergy Clin Immunol Pract 2018; 6:1162-70.
  33. Hoskin B, Ortiz B, Paknis B, Kavati A. Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. Curr Med Res Opin 2019; 35:1387-95.
  34. Tanaka T, Hiragun M, Hide M, Hiragun T. Analysis of primary treatment and prognosis of spontaneous urticaria. Allergol Int 2017; 66:458-62.
  35. Ferrer M, Bartra J, Giménez-Arnau A et al. Management of urticaria: not too complicated, not too simple. Clin Exp Allergy 2015; 45:731-43.
  36. Cappuccio A, Limonta T, Parodi A et al. Living with chronic spontaneous urticaria in Italy: a narrative medicine project to improve the pathway of patient care. Acta Derm Venereol 2017; 97:81-5.
  37. Williams PV, Kavati A, Pilon D et al. Treatment patterns, healthcare resource utilization, and spending among Medicaid-enrolled children with chronic idiopathic/spontaneous urticaria in the United States. Dermatol Ther 2018; 8:69-83.
  38. Maurer M, Raap U, Staubach P et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy 2019; 49:655-62.
  39. Eun S, Lee J, Kim D, Yoon H. Natural course of new-onset urticaria: results of a 10-year follow-up, nationwide, population-based study. Allergol Int 2019; 68:52-8.
  40. Kozel M, Mekkes J, Bossuyt P, Bos J. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 2001; 45:387-91.
  41. van der Valk P, Moret G, Kiemeney L. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol 2002; 146:110-3.
  42. Hiragun M, Hiragun T, Mihara S et al. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy 2013; 68:229-35.
  43. Curto-Barredo L, Riba-Archila L, Roura-Vives G et al. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venerol 2018; 98:641-7.
  44. Folci M, Heffler E, Canonica GW et al. Cutting edge: biomarkers for chronic spontaneous urticaria. J Immunol Res 2018; 2018:5615109.
  45. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007; 34:294-301.
  46. Kim J, Har D, Brown L, Khan D. Recurrence of chronic urticaria: incidence and associated factors. J Allergy Clin Immunol Pract 2018; 6:582-5.
  47. Kolkhir P, Altrichter P, Hawro T, Maurer M. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy 2018; 73:940-8.
  48. Pérez-Ferriols A, Barnadas M, Gardeazábal J et al. Solar urticaria: epidemiology and clinical phenotypes in a Spanish series of 224 patients. Actas Dermosifiliogr 2017; 108:132-9.
  49. Deza G, Brasileiro A, Bertol M et al. Acquired cold urticaria: clinical features, particular phenotypes, and disease course in a tertiary care center cohort. J Am Acad Dermatol 2016; 75:25-9.
  50. Chansakulporn S, Pongpreuksa S, Sangacharoenkit P et al. The natural history of chronic urticaria in childhood: a prospective study. J Am Acad Dermatol 2014; 71:663-8.

Page Navigation